REVIVA PHARMACEUTICALS HOLDINGS, INC.
RVPH · OTCMCIK 1742927fmd_11KT8S3X3W89KDP4S169HP7KGKManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Dec 01, 2017 to Sep 30, 2026, 39 periods
| Line item | FY2019 | FY2020 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Net interest income | – | 1 | – | – | – | – | – | – |
| Research and development | 0 | – | 0 | 5 | 23 | 31 | 23 | 12 |
| Total operating expenses | 0 | – | 2 | 10 | 28 | 40 | 31 | 20 |
| Operating income | (0) | – | (2) | (10) | (28) | (40) | (31) | (20) |
| Interest expense | 0 | – | 1 | – | – | 0 | 0 | 0 |
| Interest and investment income | 0 | – | – | – | – | 0 | 0 | 0 |
| Other non-operating income (expense) | (0) | – | (1) | 2 | (0) | 0 | 1 | 0 |
| Income before taxes | (1) | – | (4) | (9) | (28) | (39) | (30) | (20) |
| Income tax expense | 0 | – | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (1) | – | (4) | (9) | (28) | (39) | (30) | (20) |
| Net income | (1) | – | (4) | (9) | (28) | (39) | (30) | (20) |
| Net income to common shareholders | – | (1) | – | – | – | – | – | – |